Effects of Grape Seed Proanthocyanidin Extract on Obesity

Abstract

Obesity is a chronic metabolic disease resulting from excessive fat accumulation and/or abnormal distribution caused by multiple factors. As a major component of metabolic syndrome, obesity is closely related to many diseases such as type 2 diabetes mellitus, hyperlipidemia, hypertension, coronary heart disease, stroke and cancer. Hence, the problem of obesity cannot be ignored, and recent studies have shown that grape seed proanthocyanidin extract (GSPE) has an antiobesity effect. This paper systematically reviews the research progress and potential mechanism of GSPE emphasizing on obesity prevention and treatment.

Introduction

Obesity is a group of heterogeneous diseases which is associated with many factors, such as genetic factors, bad eating habits, less physical activity, endocrine and metabolic system disorders [1, 2, 3], alteration of intestinal flora [4], brown fat dysfunction [5], dysfunction of the nervous system hypothalamus ventrolateral nucleus hunger center and ventromedial nucleus satiety center [6], the disturbance of the biological clock [7]and so on. Complex and diverse causes contribute to the high incidence of obesity: the number of obese people in the world has increased from 105 million in 1975 to 641 million in 2014 [8]. In a nutshell, obesity poses a serious threat to the health of individuals, and more and more evidence shows that obesity is an important risk factor affecting the morbidity and mortality in cardiovascular diseases; also, overweight can increase the mortality of adults suffering from cardiovascular diseases [9]. The body mass index has a linear relationship with the mortality rate of coronary artery disease, stroke and diabetes mellitus [10]. Even modest weight loss can also reduce the risk of these complications [11]. In addition, obesity can lead to gastrointestinal disorders, joint and muscle diseases, respiratory system problems and psychological problems [12, 13]. In short, obesity is an increasingly serious global public health problem, which seriously affects the daily life of obese people and increases the risk of mortality.

How to prevent and treat obesity has been the focus of attention. Behavioral exercise and drug therapy [14], surgical weight loss [15] and dietary intervention therapy [16] have been the focus of research. But the effect of behavioral exercise on weight loss is slow and obviously unsuitable for obese patients with cardiovascular diseases; every weight loss drug has its own unique risk characteristics, so the doctor needs to fully understand drug contraindications and the differences among obese individuals [17]. More importantly, there is still a lack of long-term experimental studies on whether drug weight loss can cause side effects. Besides, the way of surgical weight loss has been considered controversial for a long time. It can reduce obesity in a short period of time, as 10–30% of patients who undergo gastric bypass surgery lose weight by 40 or 50% [18]. However, current evidence shows that the benefits of surgical weight loss are not universal. A considerable proportion of patients will experience weight rebound and recurrence of diabetes [19]. Although exercise, drugs and surgery can achieve effective weight loss, they have limitations, risks and instability, and are not suitable for all obese patients. In this context, a safe and reliable method of reducing obesity with fewer side effects is urgently required by obese people. Compared with behavior, drugs and surgical treatment, dietary strategies for losing weight or improving obesity-related conditions seem to be more anticipated. The use of plant-derived polyphenol flavanone, which has few side effects and widely exists in nature, has aroused interest among many dietary interventions [20, 21, 22]. The results of various animal and in vitro experiments show that polyphenols play a beneficial role in the complications of adipocyte-related pathology and dyslipidemia [23].

Grape seed proanthocyanidin extract (GSPE) is a flavonoid polyphenolic compound extracted from grape seeds. It is composed of +catechin, −epicatechin gallate, −epicatechin gallate and −epigallocatechin via C4–C6 or C4–C8 bond links. It exists in the form of monomer and polymer (Fig. 1) [24, 25]. Compared with other plant-derived polyphenols; GSPE has more beneficial health properties, including the ability to modify early cerebrovascular injury caused by hypertension [26], protection of the myocardium from injury [27, 28], prevention and treatment of diabetes and its complications [29], alleviation of exercise fatigue [30] and prevention of obesity and inflammatory reaction [31, 32]; it is considered as one of the most effective plant antioxidants, and one of the most effective free radical scavengers [33, 34]. By studying the relationship between GSPE and obesity, we found that GSPE has many activities, such as lowering blood lipid, improving the intestinal flora, regulating the metabolism and so on [35, 36]. It can effectively prevent obesity in many ways.

Fig. 1.

Structure of flavane-3-­alcohol, procyanidin dimer and procyanidin trimer.

Improving Lipid Metabolism

Correct the Imbalance of Adipokines and Insulin Resistance

Adipose tissue is an integral part of endocrine organs, and its secreted adipokines are closely related to the occurrence of obesity [37]. Adipose factors participate in regulating the metabolic balance network in vivo through autocrine, paracrine and endocrine forms. When metabolic abnormalities occur, the secretion of adipokines increases and interferes with insulin signaling pathways, increased insulin synthesis and secretion, increased apoptosis of pancreas cells and clearance of insulin by insulin degradation enzyme, resulting in peripheral insulin resistance and disorders of lipid metabolism in vivo [38]. Three groups of hamsters were given a standard diet and a control group was given a high-fat diet/GSPE solution for 12 weeks. Measuring their blood sugar, triglyceride (TG), insulin, leptin and adiponectin. It was found that GSPE prevented the increase in blood sugar, TG, insulin and insulin resistance to a certain extent, and reduced insulinemia and leptin by 16.5 and 45%, cardiac superoxide by 74%, NAD(P)H oxidase by 30%, while adiponectin levels increased by 61% compared to the high-fat diet control group, suggesting that long-term consumption of GSPE can reduce obesity development and related metabolic pathways by improving adipokine secretion and oxidative stress [39]. Aside from this, chronic supplementation of GSPE can act on insulin-sensitive cells, affect the function of pancreatic β-cells, and prevent the effect of a high-fat diet on pancreatic insulin secretion and lipid accumulation, thus improving insulin resistance. Also, it is worth noting that GSPE intake during lactation could induce insulin resistance and adiponectin resistance phenotypes in obese offspring, which indicates that GSPE had potential as a nutritional supplement during pregnancy [40].

Regulating the Function of White Adipose Tissue and Brown Adipose Tissue

Adipose tissue is divided into white (WAT) and brown adipose tissues (BAT). WAT stores energy, which is the largest energy reserve in mammals. WAT expands through hypertrophy (increased size of adipocytes) and/or proliferation (increased number of adipocytes). Obesity-related metabolic complications are associated with abnormal WAT expansion [41], because adipocyte hypertrophy is associated with insulin resistance and dyslipidemia. Compared to small adipocytes, hypertrophic adipocytes are more likely to attract inflammatory cells, have more fat-soluble and insulin resistance effects, resulting in metabolic disorders. However, proliferation can prevent metabolic changes [42]. GSPE supplementation can regulate WAT in visceral and subcutaneous tissues, reduce adipocyte hypertrophy and increase adipocyte proliferation, thus improving WAT function.

BAT has an antiobesity effect [43, 44] and excision of BAT in animals can lead to an abnormal increase in WAT [45]. Under normal conditions, it consumes energy by self-adapting heat production. Obesity was related to the decrease in BAT heat production, and the heat production in obese people was significantly lower than that in lean people [46]. This is because dietary-induced obesity can affect the function of BAT mitochondria, resulting in decreased gene expression of sirtuin protein 1, nuclear respiratory factor 1, isocitrate dehydrogenase 3γ and COX5α, and more importantly, reduced respiratory levels of mitochondria and pyruvate as well as carnitine palmitoyl coenzyme A. But chronic administration of GSPE can increase the oxidase activity of BAT cytochrome c in obese rats and correct the expression of key genes in BAT mitochondria. Mitochondrial respiratory status with pyruvate and carnitine palmitoyl coenzyme A as substrates in obese rats decreases mitochondrial function, while long-term administration of GSPE can promote mitochondrial respiration, improve mitochondrial function and increase BAT's heat production capacity, thereby increasing energy consumption to prevent weight gain [47].

Some studies have found that some bioactive chemicals can induce WAT browning. GSPE is a flavonoid polyphenol biochemical, which can regulate WAT and BAT. Whether GSPE can induce WAT browning has not been studied yet. However, a new idea has been put forward for us that GSPE may have such a potential mechanism.

Increase the Transcriptional Activity of Bile Acid-Activated FXR and Inhibit Very Low-Density Lipoprotein Assembly

Bile acid is an effective low TG preparation, inhibiting the production of hepatic fat and the secretion of TG by activating and binding bile acid receptor (FXR), eliminating lipid protein rich in TG in blood and then lowering the plasma TG level. In the liver, bile acid-activated FXR upregulates the expression of orphan nuclear receptor small isodimer chaperones, thereby inhibiting the expression of transcription factor sterol regulatory element binding protein 1c (SREBP1), resulting in a decrease in fatty acid (FA) synthesis in the liver and an increase in plasma TG catabolism. Therefore, FXR activity plays a key role in the control of TG, cholesterol, bile acid and glucose homeostasis. GSPE can regulate bile acid and lipid metabolism in vivo [48]. By comparing the effects of GSPE on wild type and FXR-null type mice, it was found that GSPE decreased the TG level of wild type mice without affecting the plasma total cholesterol level, but it had no significant effect on the plasma TG level of FXR-null type mice. This indicated that GSPE relied on the FXR pathway to reduce TG and, by enhancing the cdca in CV-1 and Hela cells, to activate the transcriptional activity of FXR [49, 50]. In addition, GSPE can inhibit very low-density lipoprotein assembly [51, 52], SREBP1 activates the expression of multiple genes involved in FA and TG synthesis, and other components of the lipid metabolism regulation mechanism. Its transcriptional inhibition is related to the synthesis and release of low FA and TG in the liver, leading to hypolipidemia [53]. In conclusion, GSPE can be used as a co-activator of bile acid-dependent FXR activity. GSPE can reduce liver FA synthesis and increase plasma TG catabolism by activating FXR, transient upregulation of orphan nuclear receptor small isodimer chaperone expression [54] and subsequent downregulation of SREBP expression, thereby reducing body fat content.

Inhibiting the c-Jun Aminoterminal Kinase Pathway

Obesity is associated with an abnormal increase in c-Jun aminoterminal kinase (JNK) activity [55]. JNK is an important component of mitogen-activated protein kinase, also known as stress-activated protein kinase [56]. JNK protein-coding genes include JNK1, JNK2 and JNK3. JNK1 and JNK2 are expressed in all tissues of the body. JNK3 is only expressed in the brain, heart and testis [57, 58]. In obese mice, increased lipid toxicity pressure activates JNK, and JNK activation leads to insulin resistance [59]. By comparing the effects of GSPE on lipid deposition in mice fed with a normal diet and high-fat diet, it was found that GSPE decreased the expression of FA synthase, C/EBPα protein and MPARγ peroxidase receptor mRAN, which are the lipid production-related genes, through inhibiting the JNK pathway effectively reduced fat deposition [60, 61, 62] and showed a dose dependency. In a short time, the oral low dose of 25 mg/kg/day GSPE can reduce the size of WAT in the retroperitoneum, mesentery, epididymis and inguinal region, and prevent fat accumulation [63]. Comparing low, medium and high concentrations of GSPE (100, 200, 400 mg/kg/day), the low dose group had the best comprehensive lipid-lowering effect [64]. Among 50/100/150 mg/kg/day GSPE, 150 mg/kg/day GSPE had the best effect on reducing blood lipid level, body weight, glucose and insulin tolerance in obese mice. The study of dosage-combined administration methods found that the best way to treat obesity metabolic disorder was intermittent administration of 500 mg/kg at intervals of more than 1 week [65]. A single acute dose of GSPE was satisfactory, increased lipid oxidation of subcutaneous adipose tissue and increased total energy consumption. These combined effects resulted in weight loss. In addition, supplementation of GSPE with aerobic exercise can also reduce obesity in rats fed with a high-fat diet [66, 67]. Different doses and different ways can reduce fat deposition and obesity, but precise dosage and supplementation methods as well as auxiliary measures are still valuable for research.

Normalizing the Levels of microRNA-33 and microRNA-122

MicroRNA is a small noncoding RNA with a length of about 22 nucleotides, which horizontally regulates gene expression after transcription. MicroRNAs are involved in almost all biological processes, affecting most metabolic pathways [68]. Obesity leads to overexpression of microRNA-33 and microRNA-122 in the rat liver [69, 70] but microRNA-33 and microRNA-122 are the main regulators of liver fat metabolism. In order to evaluate whether chronic intake of GSPE can improve the tolerance to lipid overload, inhibit the expression of hepatic microRNA-33 and microRNA-122, and reduce the increase in TGs in healthy rats after a meal, a dose-response experiment was conducted at 5, 15, 25 or 50 mg/kg GSPE for 3 weeks. The study found that all doses of GSPE inhibited liver expression of miR-33a and miR-122, and reduced plasma and liver lipid levels [71] in a dose-dependent manner.

Interfere with Adipocyte Differentiation

Fat differentiation is a complex process, which is highly regulated by hormones, cytokines and growth factors. Some molecules such as insulin, insulin-like growth factor-1, glucocorticoid (such as dexamethasone), the cAMP producer isobutyl methylxanthine, and thiazolidinedione have been shown to trigger 3T3-L1 (preadipocyte) to differentiate into adipocytes [72]. GSPE can interfere with the differentiation process of 3T3-L1 adipocytes at the early stage of differentiation. Peroxisome proliferative activation receptor-γ₂ is the main regulator of adipocyte differentiation and plays a central role in the lipolysis of adipocytes by GSPE. It interferes with the development of adipocytes through cell cycle and makes them fully differentiate [73]. In evaluating the effects of GSPE on differentiation, proliferation and lipolysis of porcine adipocytes, it was found that GSPE treatment inhibited preadipocyte differentiation and proliferation, reduced lipid accumulation, decreased expression of peroxisome receptor γ and FA binding protein 4 and activity of TG-3-phosphate dehydrogenase by RNA. In mature porcine adipocytes, GSPE reduced lipid content and glycerol phosphate dehydrogenase activity, promoted free FAs and glycerol release; mRNA expression of key lipopolysaccharide transcription factors such as hormone sensitive lipase and fat TG lipase increased [74]. Therefore, it can be concluded that GSPE helps by reducing the formation of new adipocytes to prevent the development of obesity and obesity-related diseases [75, 76].

Improving Intestinal Flora

Regulating the intestinal microflora may be one of the mechanisms of GSPE affecting metabolism. Normal intestinal microflora can promote food metabolism, enhance immunity, participate in mediating fat absorption, transportation, storage and metabolism. Long-term high-fat diet can lead to intestinal microflora disorder, abnormal increase in intestinal permeability, endotoxin, flagellum (the elongated curved filaments of proteins attached to the bodies of certain bacteria), and other harmful substances entering the blood through the intestinal wall and ultimately leading to chronic inflammation and obesity [77]. The intestinal flora is mainly composed of Bacteroides (Gram-negative, spore-free, obligate anaerobic bacilli), Firmicutes (Gram-positive bacteria), and Bifidobacteria (Gram-positive, inactive, rod-shaped, sometimes bifurcated, strictly anaerobic bacteria). Bacteroides participate in the absorption of nutrients and maintain the normal physiological function of the intestinal tract, more Firmicutes than Bacteroides in the intestine can lead to increased energy absorption in the intestinal tract, and excessive energy deposition can lead to obesity. GSPE can modify the intestinal microflora for a short time and increase the number of Bacteroides, decrease the number of Firmicutes and the content of butyric acid in the cecum, and regulate dominant bacteria (Fig. 2) [78]. The 16S rRNA amplifier sequencing technique was used to analyze the intestinal flora structure of a high-fat model and GSPE model. After gavage for 6 weeks, the abundance of Bifidobacterium, Bacteroides and Akkermansia in the GSPE group increased significantly, and the intestinal mucosal degrading bacteria Akkermansia muciniphila increased 70-fold, the intestinal permeability in the GSPE group was significantly lower than that in the high-fat group. GSPE promoted the transition of abnormal intestinal flora structure to normal induced by high-fat diet, repaired intestinal permeability, inhibited chronic inflammation induced by harmful external antigens such as intestinal microorganisms [79, 80], significantly reduced plasma inflammatory factors such as tumor necrosis factor-α, interleukin-6 or monocyte chemoattractant protein-1, improved macrophage infiltration of fat and liver tissue, regulated bacterial content such as that of Clostridium or Prevotella [81], and it was observed that chronic supplementation of GSPE can protect obese rats from diet-induced intestinal changes [82].

Fig. 2.

The mechanism of GSPE on obesity induced by high-fat diet (HFD). Chronic GSPE supplementation significantly changed the composition of the intestinal flora, i.e. the number of thick-walled bacteria (as shown in the gray bacterium) decreased, while the number of bacteria (red bacterium) and bifidobacteria (green bacterium) increased. The change of the microbial community is related to the increase in butyrate production. Butyrate further increased the secretion of GLP-1 in intestinal L cells and ultimately enhanced metabolic function to prevent obesity.

Reduce Food Intake

Food intake is related to energy balance, which is a dynamic process. There is an interaction between food intake and energy consumption (Fig. 3) [83]. For humans, appetite control is a complex process, and feeding is affected by the hypothalamus and brain centers including the brainstem and hippocampus, as well as the stomach, intestine, liver, thyroid, peripheral adipose tissue, psychological and social behavior [84]. The hypothalamus regulates long-term energy balance and weight by integrating fat hormone signals; the feeding and anorexia neurons in different regions participate in the regulation of food intake by regulating the sensitivity of the posterior brain to short-term satiety hormones [85]; the gastrointestinal endocrine cells produce and secrete satiety hormones, which inhibit hunger, promote satiety and regulate eating behavior through the posterior cerebral circuit. The composition of food nutrients also affects satiety and appetite; foods with high protein content have the strongest satiety and those with high fat content have the weakest satiety [86].

Fig. 3.

The main influence formula of the energy balance framework on appetite control. Green arrows indicate the process of stimulating feeding, while red arrows indicate the process of inhibiting feeding [98]. GSPE increases the secretion of gastrointestinal hormones that inhibit feeding, such as glucagon-like peptide (GLP-1), peptide YY (PYY), cholecystokinin (CCK) and ghrelin.

In the gastrointestinal mechanism, GSPE treatment can inhibit digestive enzymes and nutrient digestion and absorption, thereby reducing food intake [87]. However, some studies have shown that GSPE inhibits intestinal β-glucosidase, improves intestinal amylase, lipase and protease, and improves digestive capacity [88, 89]. The inconsistency of the experimental results may be due to the small amount of enzymes in the intestinal tract of rats, and individual differences are considerably large. Hence, the result error is caused, and the results need to be verified by further experimental research. In addition, GSPE can reduce gastrointestinal motility. In fasting animals, GSPE inhibits 60% of intestinal activity and 80% more strongly after feeding. In the absence of hepatic glucose production on the fasting stomach, the production of intestinal glucose is the necessary condition for maintaining blood glucose homeostasis [90]. Acute GSPE treatment inhibits intestinal gluconeogenesis, downregulates the expression of the glucose transporter Glut-2 and glucokinase in the liver and pancreas [91], reduces the uptake of glucose in the liver and pancreas, resulting in increased levels of portal vein glucose. During fasting, the portal vein glucose level maintained satiety to a certain extent [92]. When glucose is present in the intestine, it stimulates the secretion of intestinal hormones related to satiety in the colon, such as glucagon-like peptide (GLP-1), peptide YY, cholecystokinin and ghrelin.

In the central nervous system, the level of GLP-1 in plasma was elevated by giving 1 g GSPE/kg to fasting rats [93]. GLP-1 is a peptide hormone coded by the human glucagon gene and secreted by intestinal L cells. It can inhibit glucagon secretion, inhibit appetite and feeding, delay gastric emptying and increase satiety [94]. The increase in GLP-1 is a key mediator of GSPE influencing food intake. Sisley et al. [95] have also shown that neuronal GLP-1 receptors mediate the anorexia effect of liraglutide (a persistent GLP-1 agonist). At the same time, GLP-1 activated POMC/CART neurons in the hypothalamus [96], indirectly inhibited neuropeptide Y/agouti-related peptide neurons through β-aminobutyric acid transmission, and together produced signals to reduce food intake, which indicated that GSPE affected the hypothalamic center [97], and then controlled food intake. However, the inhibiting effect of GSPE on food intake needs to be exerted at a specific dose without external pressure and calmness. The dosage of 125 mg/kg GSPE did not reduce food intake. The dosage of 250 mg produced a 15% inhibiting effect, which increased to 25% at 500 mg, but had a negative effect at 1,000 mg. In conclusion, GSPE affects food intake by modifying the GLP-1 signal, inhibiting digestive enzymes and reducing gastrointestinal motility at appropriate doses under nonstress conditions.

Adjusting the Peripheral Clock

Obesity is related to a disorder of the biological clock. The biological clock is a physiological regulation mechanism of the periodic changes of the biological adaptation to the external environment. It can be divided into the central biological clock and the peripheral biological clock. The central clock is regulated by light, and the peripheral clock is also affected by related hormones and food besides the light regulation (Fig. 4). Obesity is related to fat accumulation in vivo, clock gene expression is related to abdominal fat content, the day-night cycle is related to lipid balance and metabolism in vivo [99, 100]. Obesity caused by diet can lead to overexpression of some core clock and clock genes [101]. In order to see whether it can regulate the liver and intestine of healthy and obese rats, rats were given different doses of GSPE. It was found that GSPE administration inhibited the interference of clock genes in the liver and intestine [102]. WAT is most sensitive to GSPE [103]. In conclusion, GSPE has a certain role in regulating obesity clock genes. However, it cannot be inferred whether GSPE changes the clock gene first, then the lipid metabolism, or whether the lipid metabolism comes first. Therefore, whether proanthocyanidins can directly regulate the phase, amplitude and/or cycle of peripheral and central clocks remains to be further studied.

Fig. 4.

GSPE regulates the relationship between biological clock and metabolism. GSPE inhibits the interference of the liver and intestine with the peripheral clock and improves the disturbance of the biological clock.

Conclusion and Prospect

Obesity is a chronic metabolic disease, and there are many mechanisms affecting obesity. GSPE can improve lipid metabolism, reduce fat deposition, improve insulin resistance, increase TG decomposition, improve BAT heat production capacity, improve intestinal flora, reduce food intake, improve the peripheral clock to reduce obesity or prevent further development of obesity. However, most of the studies on the effects of GSPE on obesity remain in animal and cell experiments, and some of the mechanisms of action are less studied. The reliability of the experimental results needs to be further tested. The precise mechanism is not clear. The effect of GSPE on improving lipid metabolism in vivo through different mechanisms has been confirmed. However, whether GSPE can reduce body weight is still controversial. Some experimental results showed that GSPE could reduce the body weight of mice, but there were also some experimental results that showed that the body weight of mice did not change, which may be due to the errors caused by different experimental models, doses and time of use. Future research can be further explored from the following aspects: (1) continue to explore the mechanism between GSPE and obesity, study the relationship between chronic supplementation of GSPE and regulation of the biological clock; (2) rigorously designed large-scale randomized trials or meta-analyses of current research and results; (3) clinical exploration of GSPE prevention and treatment of obesity, the optimal dose for obese people.

Statement of Ethics

The authors have no ethical conflicts to disclose.

Disclosure Statement

No potential conflicts of interest were disclosed.